Magenta Therapeutics
Magenta Therapeutics was a Cambridge, MA-based clinical-stage biotechnology company founded in 2015 developing stem cell-based therapeutics, including conditioning regimens for bone marrow transplant and gene therapy. The company is now delisted from Nasdaq.
- Company typePublic
- Founded2015
- HeadquartersCambridge, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Magenta Therapeutics does
Magenta Therapeutics was a Cambridge, Massachusetts-based clinical-stage biotechnology company founded in 2015 to develop therapeutics based on stem cell biology. The company's focus was on conditioning regimens (antibody-drug conjugate-based approaches) and stem cell mobilization products intended to enable or improve bone marrow transplantation and gene therapy procedures. Strategic investor participation from Be The Match BioTherapies in multiple rounds signals a deliberate orientation toward the transplant and hematology clinical ecosystem. The company was publicly traded on Nasdaq under the ticker MGTA but has since been delisted, reflecting an unsuccessful commercial trajectory.
Magenta operated a pre-revenue business model typical of clinical-stage biotechs: capital was raised through successive equity financings (six rounds totaling approximately $405.9M from 2016 to 2021) and deployed into R&D and clinical development of its pipeline candidates. Investor composition evolved from early-stage venture (Atlas Venture, Third Rock Ventures, Google Ventures) through crossover and healthcare-specialist funds (Deep Track Capital, Great Point Partners, Janus Henderson, OrbiMed, TCG Crossover). There is no evidence in source materials of licensing revenue, royalties, or commercial product sales. The company's customer base in any commercial sense is therefore non-existent at the time of available data, with eventual customers presumed to be hospital transplant centers, specialty hematology practices, and gene therapy programs.
The company's go-to-market upon commercialization would have relied on the standard biotech model of either independent specialty sales targeting bone marrow transplant centers, partnership with larger pharma for commercialization, or co-promotion arrangements. Scientific founding was anchored by co-founder David Scadden, a prominent Harvard/MGH stem cell biologist. Leadership at the time of available data included chairman roles held by Alison Lawton and Michael Bonney, with Steve Mahoney serving as CFO/COO and Bastiano Sanna as COO. Reported annual operating losses were in the tens of millions of dollars, consistent with a 51-100 employee clinical development organization.
Magenta Therapeutics firmographics
Firmographics- Name
- Magenta Therapeutics
- Legal name
- Magenta Therapeutics
- Website
- https://magentatx.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Magenta Therapeutics was a Cambridge, MA-based clinical-stage biotechnology company founded in 2015 developing stem cell-based therapeutics, including conditioning regimens for bone marrow transplant and gene therapy. The company is now delisted from Nasdaq.
- Ownership category
- akta.pro rank
Magenta Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411), Scientific Research and Development Services (5417)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
Keywords
Where Magenta Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Magenta Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Magenta Therapeutics product offering
Product offeringCore offering
Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics based on stem cell biology, with a focus on hematopoietic stem cell transplant conditioning and immune reset for patients with hematologic diseases and genetic disorders. The company advances biologic drug candidates intended for clinical use in transplant and immune-mediated disease settings.
Differentiator
Problem solved
Functional benefit
Companies that use Magenta Therapeutics
Customer profileIdeal customer profiles1 record
Magenta Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Magenta Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights3 records
Magenta Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Beam Therapeutics: Base-editing biotech with ex vivo HSC programs (e.g., for sickle cell disease). Comparable in that its therapeutic approach depends on the same transplant infrastructure and conditioning workflows Magenta targets.
- Editas Medicine: Clinical-stage gene editing company with ex vivo HSC programs. Operates in adjacent transplant infrastructure, sharing the same conditioning and mobilization workflows Magenta seeks to improve.
- Vertex Pharmaceuticals: Through its Casgevy partnership with CRISPR Therapeutics, Vertex is a major commercial player in stem cell-based gene therapy. Operates at scale in the same downstream indications Magenta's enabling platform addresses.
- CRISPR Therapeutics: Commercializing Casgevy (exa-cel) for sickle cell disease and beta-thalassemia. Uses hematopoietic stem cell editing requiring conditioning, putting it in adjacent competition for the same transplant infrastructure and donor ecosystem Magenta targets.
Direct peers
- bluebird bio: Gene therapy company with ex vivo lentiviral therapies (sickle cell, beta-thalassemia, cerebral adrenoleukodystrophy) that depend on conditioning regimens overlapping with Magenta's transplant-conditioning focus.
- Vor Biopharma: Develops engineered hematopoietic stem cell transplants (eHSC) with engineered CD33 to enable targeted conditioning. Overlaps directly with Magenta's conditioning-plus-transplant approach and addresses the same transplant bottlenecks.
- Jasper Therapeutics: Clinical-stage biotech developing JSP191, an anti-CD117 antibody for conditioning prior to allogeneic hematopoietic stem cell transplant and gene therapy. Directly competes with Magenta's conditioning program in the same transplant-conditioning niche.
- Actinium Pharmaceuticals: Develops Iomab-B and other targeted conditioning agents for hematopoietic stem cell transplantation. Targets the same transplant-conditioning indication as Magenta with a different modality (radioimmunotherapy).
Emerging players
- Intellia Therapeutics: In vivo and ex vivo CRISPR-based gene editing company with HSC-adjacent programs. Shares the broader stem cell and gene therapy ecosystem in which Magenta's conditioning platform operates.
- Allogene Therapeutics: Clinical-stage allogeneic CAR-T company using healthy donor T cells. Adjacent because allogeneic cell therapies intersect with the same donor, mobilization, and conditioning infrastructure Magenta targets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights6 records
Customer concentration
Magenta Therapeutics social profiles
Digital presenceMagenta Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Magenta Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Magenta Therapeutics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Magenta Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Magenta Therapeutics
What does Magenta Therapeutics do?
Magenta Therapeutics is a clinical-stage biotechnology company developing therapeutics based on stem cell biology, with a focus on hematopoietic stem cell transplant conditioning and immune reset for patients with hematologic diseases and genetic disorders. The company advances biologic drug candidates intended for clinical use in transplant and immune-mediated disease settings.
Is Magenta Therapeutics a public or private company?
Magenta Therapeutics is a public company. It is classified as public and is currently operating.
When was Magenta Therapeutics founded?
Magenta Therapeutics was founded in 2015. It employs 51 to 100 people.
Where is Magenta Therapeutics based?
Magenta Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are Magenta Therapeutics's main competitors?
Broad incumbents on record are Beam Therapeutics, Editas Medicine, Vertex Pharmaceuticals and CRISPR Therapeutics. Direct peers are bluebird bio, Vor Biopharma, Jasper Therapeutics and Actinium Pharmaceuticals. Emerging players are Intellia Therapeutics and Allogene Therapeutics.
Does Magenta Therapeutics have an API?
No public API is recorded for Magenta Therapeutics.
What industry is Magenta Therapeutics in?
Magenta Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325411 and its SIC code is 2833.